## 北 斗 嘉 藥 業 股 份 有 限 公 司 **BAYTACARE PHARMACEUTICAL CO., LTD.\*\***

(formerly known as 東北虎藥業股份有限公司 (Northeast Tiger Pharmaceutical Co., Ltd.\*\*)) (a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8197)

## REVISED FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON 31 MAY 2017 (OR AT ANY ADJOURNMENT THEREOF)

Numbe I/We <sup>(n</sup>	r of shares relevant to the proxy form: (line 1)	Domes	tic Shares/H Shares*
of			
being Dome	the registered shareholder of Baytacare Pharmaceutical Co. Ltd.** (the "Company stic Shares/H Shares* hereby appoint (note 3) the chairman of the Annual	") holding General Meet	ing (the "AGM")
or	our proxy or proxies to attend on my/our behalf the AGM (or any adjournment thereo	f) to be held at I	aval 40. Lang Vuon
Chuang 2:00 p.	gz Zhan Building, No. 2010 Baoan South Road, Luohu District, Shenzhen, The People's m. and to vote for me/us on the undermentioned resolutions as indicated. Failure to c o vote at his/her own discretion:	Republic of Chin	a on 31 May 2017 at
рголу			,
	ORDINARY RESOLUTIONS	FOR (Note 4)	AGAINST (Note 4)
1.	To consider and approve the audited financial statements and the report of the auditors of the Company for the year ended 31 December 2016.		
2.	To consider and approve the report of the directors of the Company for the year ended 31 December 2016.		
3.	To consider and approve the report of the supervisory committee of the Company for the year ended 31 December 2016.		
4.	To consider and approve the re-appointment of Pan-China (H.K.) CPA Limited as the Company's auditors and to authorize the board of directors of the Company to fix their remuneration.		
5.	To empower the executive directors of the Company to exercise the authority for the determination of incentive bonus to the relevant person of the Company as a motivation for the contribution of efforts to the development of the Company, if any.		
6.	To consider and approve the remuneration proposals for the directors and supervisors of the Company for the year ended 31 December 2016.		
7.	To consider and approve the election of Mr. Shi Peng (師鵬) as a non-executive director of the Company.		
8.	To consider and approve the election of Mr. Gao Zhikai (高志凱) as an independent non-executive director of the Company.		
8(a).	To consider and approve the re-election of Mr. Wang Shaoyan (王少岩) as an executive director of the Company.		
8(b).	To consider and approve the re-election of Ms. Cui Bingyan (崔冰岩) as an executive director of the Company.		
	To consider and approve the re-election of Mr. Qin Haibo (秦海波) as an executive director of the Company.		
8(d).	To consider and approve the re-election of Mr. Cao Yang (曹陽) as a non-executive director of the Company.		
8(e).	To consider and approve the re-election of Mr. Zhao Zhen Xing (趙振興) as an independent non-executive director of the Company.		
	To consider and approve the re-election of Ms. Hui Lai Yam (許麗欽) as an independent non-executive director of the Company.		
	To consider and approve the election of Mr. Jiang Xiaobin (姜曉斌) as an executive director of the Company.		
	To consider and approve the election of Mr. Yang Yulin (楊育林) as an independent non-executive director of the Company.		
	To consider and approve the election of Ms. Han Xue (韓雪) as a member of the supervisory board of the Company.		
8(j).	To consider and approve the re-election of Ms. Yang Lixue (楊腐雪) as a member of the supervisory board of the Company.		
8(k).	To consider and approve the re-election of Ms. Meng Shuhua (孟淑華) as a member of the supervisory board of the Company.		
8(1).	To consider and approve the re-election of Ms. Lin Xiarong (林夏容) as a member of the supervisory board of the Company.		
SPECIAL RESOLUTIONS		FOR (Note 4)	AGAINST (Note 4)
9.	To consider and approve the mandate on authorizing the board of directors of the Company to allot, issue and deal with H shares of the Company.		
10.	To consider and approve the mandate on authorizing the board of directors of the Company to allot, issue and deal with domestic shares of the Company.		
11.	To consider and approve the proposal regarding adoption of a share option scheme of the Company.		

Signed this\_

Notes:
1. Please fill in the number of shares registered in your name(s) and the number of shares relevant to this proxy form. Failure to complete the aforesaid shares will deem this proxy form to relate to all

Signature (Note 6):

\_day of\_

- Please fill in the number of shares registered in your name(s) and the number of shares relevant to this proxy form. Failure to complete the aforesaid shares will deem this proxy form to relate to all shares registered in your name(s) in the Company.

  Full name(s) and address(es) to be inserted in BLOCK CAPITALS.

  If you are a shareholder who is entitled to attend and vote at the AGM, you are entitled to appoint one or more proxies to attend instead of you and to vote on your behalf. A proxy need not be a member of the Company, but must attend the AGM in order to represent you. If the proxy other than the chairman is preferred, strike out "the chairman of the Annual General Meeting (the "AGM") or" herein inserted and insert the name and address of the proxy or proxies desired in the space provided. If they are left blank, the Chairman of the AGM will act as your proxy. Any alteration made to this proxy form must be initialed by the person who completes it.

  Important: If you wish to vote for a resolution, place a """ in the box marked "FOR". If you wish to vote against a resolution, place a "X" in the box marked "AGAINST". Failure to complete the boxes will entitle your proxy to cast your vote at his/her discretion. Your proxy or proxies will be entitled to vote at his or her discretion on any resolution properly put to the AGM or any adjournment thereof other than those referred to in the notice covering such meeting.

  The description of these resolutions is by way of summary only. The full text appears in the notice of the AGM dated 12 April 2017 and the supplemental notice of the AGM dated 12 May 2017.

  The proxy form must be signed by you or your attorney duly authorised in writing.

- The proxy form must be signed by you or your attorney duly authorised in writing or, in the case of a corporation, must be either under its common seal or under the hand of an officer or attorney duly authorised in writing.

  A proxy shall be appointed by a written instrument signed by the appointer or its attorney. If the proxy form is signed by the attorney of the appointer, the power of the competency or other authorisation document(s) which have been notarised together with the completed proxy form, must be delivered to the registered address of the Company at No. 3. No. 2 Road, Jilin Hi-Tech Development Zone, Jilin City, Jilin Province, the People's Republic of China (for holders of domestic shares of the Company) or to the H share registrator of the Company, Com

- Delete the inappropriate
- For identification purpose only